Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 2/20 | 0.43 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199687 | 1.00 | POLB (0.47) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL18884425 | 0.94 | SMN1; SMN2 (0.49) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL16067903 | 0.94 | SMN1; SMN2 (0.49) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL17560404 | 0.85 | SMN1; SMN2 (0.40) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| Hydrochloric Acid SCHEMBL17560460 | 0.84 | SMN1; SMN2 (0.39) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL22978787 | 0.80 | ALDH1A1 (0.45) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL3898404 | 0.79 | HSD17B10 (0.41) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6908217 | 0.79 | MAPT (0.38) | POLBSMN1; SMN2ALDH1A1MAPTPEPD | |
| SCHEMBL7304578 | 0.79 | FKBP1A (0.48) | SMN1; SMN2ALDH1A1MAPTFKBP1A | |
| SCHEMBL23999544 | 0.79 | HSD17B10 (0.41) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033363-A1 | HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-03 | — | — | US | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| WO-2020245044-A1 | 1-PHENYL-5-AZINYL PYRAZOLYL-3-OXYALKYL ACIDS AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020058062-A1 | HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-03-26 | — | — | WO | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | POLB 601/4885SMN1; SMN2 2016/4885ALDH1A1 1770/4885 |
| US-20220033363-A1 | HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDES | DDT, CBR3, CAT | POLB 2694/4885SMN1; SMN2 3601/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.